Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

Make your likes visible on Facebook?

Connect your Facebook account to Prezi and let your likes appear on your timeline.
You can change this under Settings & Account at any time.

No, thanks

tek2

No description
by

Ali Meco

on 24 September 2012

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of tek2

For 2011 fiscal year end:
Total revenue: 16.6M
Total research and development spending: 19.9M

Stock Market
Toronto Stock Exchange: TKM
Around $4.00 per share and rising
14,007,855 shares out Biotechnology and Pharmaceuticals Company
RNA interference - Therapeutic drugs
Lipid nanoparticles (LNP) - Drug delivery About Tekmira Financial Information Presented by: Alicia Meconi
September 24, 2012
CH 356 TEKMIRA PHARMACEUTICALS Alnylam Pharmaceuticals Inc. Products & Collaboration Bristol-Myers Squibb Merck Pfizer Roche Talon Therapeutics, Inc. Takeda Transformational Medical Technologies Program Established in 2000
Located in Burnaby, British Columbia Five items in production
Three in Phase I trials
Two in Pre-clinical trials 370 Patents in Portfolio
180 issued
190 pending Technology RNA Interference Lipid Nanoparticles Occurs naturally in cells
Stops production of specific proteins RNA Interference Mechanism Uses small interfering RNA (siRNA)
Short segments of double stranded RNA
Located in cytoplasm
Complementary to mRNA for target protein What do siRNA do? Incorporated into RNA-induced silencing complex (RISC)
Guides siRNA to target mRNA
Destroyes mRNA by cleaving it
RISC remains stable for several weeks Multivalent RNA (MV-RNA) Improves efficiency of RNAi
Composed of three partially complementary strands of RNA Can target three mRNAs from one gene OR three mRNAs from three genes Drug delivery
siRNA and MV-RNA are unstable in the blood stream
Nucleic acids do not readily diffuse across cell membranes
Tekmira's LNP technology provides a solution Major Limitation Lipid Nanoparticles Spherical lipid bilayer
Approximately 120nm diameter
MV-RNA and siRNA are held in interior
PEG-Lipids on exterior prevent destruction by host defenses Administered intravenously Accumulate at target sites
Vascular leak is higher near tumor cells, infection, and inflammation Enter cell through endocytosis and release contents into cytoplasm Stable in the bloodstream How do LNPs work? Products RNAi and LNP are currently used in the production of five therapeutic candidates: TKM-PLK1
Potential cancer treatment
Targets polo-like kinase 1 (PLK1)
Involved in tumor cell proliferation
Inhibition prevents cell division and results in cell death
Successful in pre-clinical animal studies
Entering Phase I clinical trials TKM-Ebola
Potential treatment for hemmorrhagic fever
Successfully protects non-human primates from lethal doses of Ebola virus
Tekmira signed $34.7 million contract with US government to continue this research
Phase 1 clinical trials TKM-ApoB
Potential treatment for high cholesterol
Targets apolipoprotein B 100 in the liver
Important in cholesterol metabolism
High levels associated with increased low-density lipoprotein cholesterol
Phase 1 clinical trials WEE1/CSN5
Potential cancer treatment
Targets novel cancer genes WEE1 and CSN5
Up-regulated in breast, liver, lung, ovarian, and skin cancer
Pre-clinical work continues to evaluate potential therapeutic properties TKM-ALDH2
Potential treatment for alcohol dependance
Targets aldehyde dehydrogenase 2 (ALDH2)
Important in alcohol metabolism
Administered monthly
Potential solution to low response and compliance rates associated with other alcohol dependance treatments
Currently in pre-clinical research stages
Quote Media. (September 21, 2012). Tekmira Pharmaceuticals Corporation (TKM).
Retrieved September 22, 2012 from http://tmx.quotemedia.com/quote.php?qm_ symbol=tkm

Tekmira Pharmaceuticals. (2012). Tekmira Pharmaceuticals Corporation. Corporate.
Retrieved September 20, 2012 from http://www.tekmirapharm.com/corporate/ Overview.asp

Tekmira Pharmaceuticals. (2012). Tekmira Pharmaceuticals Corporation. Products.
Retrieved September 20, 2012 from http://www.tekmirapharm.com/Programs/Pro ducts.asp

Tekmira Pharmaceuticals. (2012). Tekmira Pharmaceuticals Corporation. Technology.
Retrieved September 20, 2012 from http://www.tekmirapharm.com/Technology/A bout_RNAi.asp References TKM-Ebola TKM-ApoB WEE1/CSN5 TKM-ALDH2 TKM-PLK1
Full transcript